Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide | Zendy

Karim Fizazi | Zendy; Neal D. Shore | Zendy; Teuvo L.J. Tammela | Zendy; Albertas Ulys | Zendy; Egils Vjaters | Zendy; S. Polyakov | Zendy; Mindaugas Jievaltas | Zendy; Murilo Luz | Zendy; B. Yа. Alekseev | Zendy; Iris Kuss | Zendy; MarieAude Le Berre | Zendy; Oana Petrenciuc | Zendy; Amir Snapir | Zendy; Toni Sarapohja | Zendy; Matthew Smith | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Author(s) -

Karim Fizazi,

Neal D. Shore,

Teuvo L.J. Tammela,

Albertas Ulys,

Egils Vjaters,

S. Polyakov,

Mindaugas Jievaltas,

Murilo Luz,

B. Yа. Alekseev,

Iris Kuss,

MarieAude Le Berre,

Oana Petrenciuc,

Amir Snapir,

Toni Sarapohja,

Matthew Smith

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2001342

Subject(s) - medicine , placebo , prostate cancer , clinical endpoint , androgen deprivation therapy , confidence interval , randomized controlled trial , surgery , cancer , pathology , alternative medicine

Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for the analysis of overall survival were immature at the time of the primary analysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research